Fritextsökning
Innehållstyper
-
TFS Trial Form Support AB
-
From powder to implant
Quality assurance for additively manufactured implants.
-
New features in ZEISS CALYPSO 2024
ZEISS CALYPSO is your universal software for dimensional metrology applications.
-
Stockholm and Uppsala jointly form a life science cluster
Stockholm and Uppsala are strengthening cooperation in medical research and biotech.
-
Anna Törner: ”Mom, do you think you’ll ever get married again?”
”I realize I’m slowly descending into that familiar statistical rabbit hole, where life’s biggest uncertainties are reduced to point estimates and confidence in...
-
“Research is always a lot of failures and a few successes”
Gene therapies open up fantastic possibilities, but they are also extremely expensive to produce. Genenova aims to change that and make the treatments accessibl...
-
Lundabolag ansöker om avnotering
Forskningsbolaget Abliva ansöker om avnotering av bolagets aktie från Nasdaq Stockholm.
-
Faster development of reliable sample handling
Festo USA has collaborated with PerkinElmer to develop a compact sample handling solution for a global leader in manufacturing medical devices. Thanks to the cu...
-
Heltysk storaffär: Biontech köper Curevac
En storaffär är på väg inom tysk vaccin- och läkemedelsindustri. Biontech har ingått avtal om att förvärva inhemska konkurrenten Curevac för omkring 1,25 miljar...
-
The art of building a biologic drug
The first biosimilar from Xbrane Biopharma was launched earlier this year, and several more are under development at the company’s facility in Solna, Sweden. “W...
-
Come see us at the upcoming events!
We have some upcoming events where you can see our latest products live!
-
Björn Arvidsson will lead research and innovation in Region Uppsala
The Swedish life science profile Björn Arvidsson has been appointed Director of Research and Innovation for Region Uppsala.
-
Advancing Drug Discovery by Combining Complex In-Vitro Models with AI-Powered 3D/4D Image Analysis
Free webinar organized by ZEISS.
-
Lilly´s Nordic manager on Mounjaro launch in Sweden: "Patients deserve respect"
Another blockbuster diabetes and obesity drug has made its way into the Swedish market – with promises of a stable supply and availability for patients. “What w...
-
Medical device quality assurance
Recordings from ZEISS Quality Innovation Days.
-
Introducing ZEISS arivis Pro 4.2
Your solution for advanced image analysis and visualization.
-
Study: Popular diabetes treatment is not associated with thyroid cancer
Concerns raised about an association between GLP-1 analogues, used to treat diabetes and obesity, and an increased risk of thyroid cancer are not supported by a...
-
Government apoints new experts to medicine and health council
Johanna Fälting, Head of Research at BioArctic, and physician Markus Lingman have been appointed as new members of the Swedish Research Council’s Subject Counci...
-
Rapid development in blood analysis – “Sweden is leading the race”
Thousands of analytical tests using just one single drop of blood. What was revealed as a hoax just a few years ago is now a reality, according to KTH professor...
-
”The importance of stratification in a statistician’s August kitchen”
Ingrid Lönnstedt writes about an experiment of her own at home and about what lessons can be learned from it, in a science column.
-
KI-studie: Nässköljning kunde ge information om KOL
Förekomsten av ett visst protein i näsan kunde användas som underlag för bedömning av KOL, i en ny studie från forskare vid Karolinska institutet.
-
An increasing number of people are falling ill with TBE – “Much more research is needed”
Tick-borne meningitis, or TBE, is an increasingly common disease in Sweden. Currently, there is a vaccine against the disease but no drugs. Researcher Anna Över...
-
Thumbs down for lecanemab in the EU – “Very surprised”
The Azheimer's drug lecanemab has received a negative assessment from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), acc...
-
Bioarctic granted Japanese patent for Parkinson’s disease candidate
Bioarctic has been granted a Japanese patent for its antibodies targeting Parkinson’s disease.